A paper published on April 20, 2012 which tested 4 candidate SARS coronavirus vaccines in both ferrets, monkeys and mice, warned: “Caution in proceeding to application of a SARS-CoV vaccine in humans is indicated”. Many mice that received a virus-like-particle vaccine died when challenged due to immune priming or antibody dependent enhancement (ADE). Although the vaccine induced immune response (producing “serum neutralizing antibodies” said to “protection against infection”), it actually set the mice up for an enhanced reaction upon challenge causing an “immunopathologic-type lung disease”, and death. [1]
Immune inhancement following coronavirus vaccines in animals is a well known issue, and in humans dates back to the use of a formalin-inactivated respiratory syncytial virus (RSV) vaccine in infants and toddlers used in 1967. [2]